As drug and vaccine manufacturers work to optimize mRNA production processes, one hurdle to overcome is mRNA’s susceptibility to breakdown by ribonuclease (RNase) enzymes introduced during production.
Cytiva
As drug and vaccine manufacturers work to optimize mRNA production processes, one hurdle to overcome is mRNA’s susceptibility to breakdown by ribonuclease (RNase) enzymes introduced during production.
Process Development Forum is an online resource for information on innovations and technologies supporting the bioprocessing development spectrum. Subscribe to the Bioprocess Development Forum eNewsletter.
© 2024 MJH Associates. All rights reserved.